



FOR IMMEDIATE RELEASE

Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting

SAN JUAN CAPISTRANO, CA — April 27, 2022 — [Allegro Ophthalmics](#), LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that two scientific posters involving risuteganib, the company's lead investigational compound in retina, will be presented during the [2022 Association for Research in Vision and Ophthalmology \(ARVO\) Annual Meeting](#). ARVO 2022 will be held May 1-4, 2022 in Denver, Colorado.

"We are excited to present these scientific findings that provide deeper insight into risuteganib's mechanism of action," said Vicken Karageozian, M.D., President and CEO of Allegro Ophthalmics, LLC. "In previous studies, risuteganib was shown to protect human RPE cells against oxidative stress-associated cellular dysfunction. At ARVO 2022, we will unveil new research focused on identifying how these processes may occur."

The schedule of scientific poster presentations is as follows:

- Title: [Cellular Uptake of Risuteganib via Endocytosis in Cultured Human RPR Cells](#)
 - Date: Tuesday, May 3, 2022
 - Time: 1:00 p.m. -- 3:00 p.m. Mountain Time
 - Location: Virtual
 - Presenter: Ping Yang, Department of Ophthalmology, Duke University School of Medicine

- Title: [Risuteganib-Directed Staining Localizes in the Retinal Pigment Epithelium of Retinal Tissue from Aged, but not Young Mice](#)
 - Date: Wednesday, May 4, 2022
 - Time: 3:00 p.m. -- 5:00 p.m. Mountain Time
 - Location: Posterboard Number F0093
 - Presenter: Jin Mo Koo, Division of Chemistry and Chemical Engineering, Caltech

-- continued --

About Allegro Ophthalmics, LLC

[Allegro Ophthalmics, LLC](#) is a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases. Pre-clinical data suggest that risuteganib (Luminate®), Allegro's lead investigational compound in retina, may simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases, such as dry AMD. A U.S. Phase 2a study with risuteganib in less advanced dry AMD met its primary endpoint of vision recovery. Expanding its oxidative stress-stabilizing portfolio, Allegro developed ALG-1007 for topical use in dry eye disease. ALG-1007 demonstrated promising results in two ex-U.S. studies in humans. For more information, visit www.allegroeye.com.

Risuteganib (Luminate®) and ALG-1007 are investigational drugs and are not approved for commercial sale.

Luminate® is a registered trademark of Allegro Ophthalmics, LLC.

###

MEDIA CONTACT:

Michele Gray

Gray Communications, LLC.

(917) 449-9250

michele@mgraycommunications.com